dm+d

Unassigned

New Medicines

Recurrent vulvovaginal candidiasis

Information

New molecular entity
Gedeon Richter
Mycovia Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

14α-demethylase (CYP51) inhibiitor
About 8% of women suffer recurrent vulvovaginal candidiasis (RVVC) [1].
Recurrent vulvovaginal candidiasis
Oral